In both humans and mice, there is evidence supporting the development of tumor-specific “memory-like” CD8+ T cells, which may be favored at the early stages of tumor growth when the extent of inflammation and levels of antigen exposure are reduced compared to later stages of cancer progression. This evidence concerns the gene CD8A and cancer.